APA (7th ed.) Citation

HWD, S., N, T., L, C., C, K., C, S., K, W., . . . M, B. (2021). MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC cancer, 21(1), 932. https://doi.org/10.1186/s12885-021-08644-4

Chicago Style (17th ed.) Citation

HWD, Siu, et al. "MONARCC: A Randomised Phase II Study of Panitumumab Monotherapy and Panitumumab Plus 5-fluorouracil as First-line Therapy for RAS and BRAF Wildtype Metastatic Colorectal Cancer: A Study by the Australasian Gastrointestinal Trials Group (AGITG)." BMC Cancer 21, no. 1 (2021): 932. https://doi.org/10.1186/s12885-021-08644-4.

MLA (9th ed.) Citation

HWD, Siu, et al. "MONARCC: A Randomised Phase II Study of Panitumumab Monotherapy and Panitumumab Plus 5-fluorouracil as First-line Therapy for RAS and BRAF Wildtype Metastatic Colorectal Cancer: A Study by the Australasian Gastrointestinal Trials Group (AGITG)." BMC Cancer, vol. 21, no. 1, 2021, p. 932, https://doi.org/10.1186/s12885-021-08644-4.